New triple inhaler aims to tame tough asthma
NCT ID NCT02676076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new inhaler that combines three medicines (beclometasone, formoterol, and glycopyrronium) against a standard two-medicine inhaler in over 1,100 adults with asthma that was not well controlled. The goal was to see if the triple combination improves lung function and reduces asthma attacks over 52 weeks. The trial has been completed, and results are being analyzed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Triple-combination inhaler (beclometasone, formoterol, glycopyrronium)
What this could lead to
If successful, this triple inhaler could offer better lung function and fewer asthma attacks for people whose asthma is not controlled with standard two-drug inhalers.
What could go wrong
This is a completed Phase 3 trial, so results are available, but the benefit over existing treatments may be modest. Side effects from the extra drug are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiesi Clinical Trial Site 276814
Rostock, Germany